HMGB1 and chronic myelogenous leukemia, BCR-ABL1 positive: The DNA-binding ability of CML-HMGB1—produced by treating recombinant HMGB1 with GLX—was markedly decreased in comparison with that of HMGB1 (Figure 2B).